BD Veritor Plus System for Rapid Detection of SARS CoV 2 01:47
BD Veritor Plu...Learn about the BD Veritor System for the Rapid Detection of S...
BD Veritor™ Sy...This video gives an overview of the set up and use of the BD V...
BD Veritor™ Pl...This video provides an overview of the BD Veritor™ Plus Analyzer.
BD 256066 BD VERITOR PLUS ANALYZER SYSTEM
BD 256066 - BD Veritor™ Plus Analyzer ROM Version 5.4 or Higher (Drop Shipped from the Manufacturer with a 2 Week Lead Time)
Now can be used for Covid-19 SARS-COV-2 Testing with BD Veritor Test Cassettes BD-256082
Other Test Cassettes that can be used with the BD Veritor™ Plus Analyzer System
Support PDF Documents
More Product Information
Are your Ready for SARS-CoV-2 Testing?
When your patients are in need of fast, reliable SARS-CoV-2 testing, turn to the BD Veritor™ Plus System. Oﬀ ering lab-quality results at the point of care, in a simple-to-operate, handheld instrument.
Simplify the testing process
Easy operation and 1-button functionality may
potentially reduce manual test processing errors
Enables intuitive sample processing with prefilled,
unitized tubes color-coded by reagent or assay type
Achieve fast, reliable results
Displays easy-to-read digital results for SARS-CoV-2 in 15 minutes
Records results on secured drive
Advanced particle technology enhances sensitivity by
using a proprietary process to produce highly stable,
modified colloidal metal particles, helping improve test performance
Adaptive read technology helps improve specificity
to reduce false-positive results by compensating for
background and nonspecific binding
Adapts easily to your workflow by offering 2 operational modes
Test device is inserted immediately into Analyzer, enabling staff to multitask while sample incubates.
Test device is inserted after incubation time is complete, allowing batches of samples to be tested
Provide result traceability
Download and display LOT number, Patient/specimen
ID, Operator ID and test records with BD Veritor™
Offers result-printing capabilities via USB port
PPA 84% (95% C.I. 67%–93%)
NPA 100% (95% C.I. 98–100%)
Negative results do not rule out SARS-CoV-2 infection
and should not be used as the sole basis for treatment
or patient management decisions, including infection
control decisions. Negative results should be considered
in the context of a patient’s recent exposures, history and
the presence of clinical signs and symptoms consistent
with COVID-19, and confirmed with a molecular assay, if
necessary, for patient management.
PLEASE NOTE: Information above in this section might be an overall summary about the product line and not in regards to the specific product. If you have any questions, Please E-mail or Call 1-877-WILBURN (1-877-945-2876).
This product hasn't received any reviews yet. Be the first to review this product!